Briacell Therap (NASDAQ:BCTX) Releases Earnings Results

Briacell Therap (NASDAQ:BCTX) posted its quarterly earnings data on Tuesday. The company reported ($2.58) EPS for the quarter, Zacks reports.

Briacell Therap Trading Up 13.9%

NASDAQ BCTX opened at $4.34 on Thursday. Briacell Therap has a 12 month low of $3.60 and a 12 month high of $98.20. The stock has a market cap of $31.47 million, a price-to-earnings ratio of -0.10 and a beta of 1.46. The company’s 50 day moving average is $4.82 and its two-hundred day moving average is $8.18.

Institutional Trading of Briacell Therap

A hedge fund recently bought a new stake in Briacell Therap stock. Citadel Advisors LLC acquired a new stake in shares of Briacell Therap (NASDAQ:BCTX) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned 1.63% of Briacell Therap at the end of the most recent reporting period. 15.42% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Briacell Therap in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $320.00.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.